These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 27569385)

  • 1. Total combining power: Technique for the evaluation of the quality control process of clostridiosis vaccines.
    Brandi IV; Santos EM; Carvalho BM; Durães CA; Farias PK; Sari RS; Cangussu AS; Pessoa A
    J Microbiol Methods; 2016 Nov; 130():164-168. PubMed ID: 27569385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality assurance of C. perfringens epsilon toxoid vaccines--ELISA versus mouse neutralisation test.
    Rosskopf-Streicher U; Volkers P; Noeske K; Werner E
    ALTEX; 2004; 21 Suppl 3():65-9. PubMed ID: 15057410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modified toxin-binding inhibition (ToBI) test for epsilon antitoxin determination in serum of immunized rabbits.
    Sobrinho EM; Cangussu AS; Brandi IV; Sari RS; Almeida AC; Colen F; Quintilio W; Santos HO
    Vet Immunol Immunopathol; 2010 Nov; 138(1-2):129-33. PubMed ID: 20709411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential protective immunogenicity of recombinant Clostridium perfringens α-β2-β1 fusion toxin in mice, sows and cows.
    Zeng J; Deng G; Wang J; Zhou J; Liu X; Xie Q; Wang Y
    Vaccine; 2011 Jul; 29(33):5459-66. PubMed ID: 21641956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and prevalidation of two different ELISA systems for the potency testing of Clostridium perfringens beta and epsilon-toxoid containing veterinary vaccines.
    Ebert E; Oppling V; Werner E; Cussler K
    FEMS Immunol Med Microbiol; 1999 Jul; 24(3):299-311. PubMed ID: 10397315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxin-neutralizing antibodies protect against Clostridium perfringens-induced necrosis in an intestinal loop model for bovine necrohemorrhagic enteritis.
    Goossens E; Verherstraeten S; Valgaeren BR; Pardon B; Timbermont L; Schauvliege S; Rodrigo-Mocholí D; Haesebrouck F; Ducatelle R; Deprez PR; Van Immerseel F
    BMC Vet Res; 2016 Jun; 12(1):101. PubMed ID: 27297520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Control of Clostridium perfringens vaccines using an indirect competitive ELISA for the epsilon toxin component - examination of the assay by a collaborative study.
    Rosskopf-Streicher U; Volkers P; Werner E
    Pharmeuropa Bio; 2004 Jan; 2003(2):91-6. PubMed ID: 14960265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A recombinant carboxy-terminal domain of alpha-toxin protects mice against Clostridium perfringens.
    Nagahama M; Oda M; Kobayashi K; Ochi S; Takagishi T; Shibutani M; Sakurai J
    Microbiol Immunol; 2013 May; 57(5):340-5. PubMed ID: 23668605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of protection afforded by a Clostridium perfringens alpha-toxoid against heterologous clostridial phospholipases C.
    Neeson BN; Clark GC; Atkins HS; Lingard B; Titball RW
    Microb Pathog; 2007 Oct; 43(4):161-5. PubMed ID: 17604945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of a Trivalent Recombinant Vaccine Against Clostridium perfringens Alpha, Beta, and Epsilon Toxins in Farm Ruminants.
    Moreira GM; Salvarani FM; da Cunha CE; Mendonça M; Moreira ÂN; Gonçalves LA; Pires PS; Lobato FC; Conceição FR
    Sci Rep; 2016 Mar; 6():22816. PubMed ID: 27004612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccines against Clostridium perfringens alpha-toxin.
    Nagahama M
    Curr Pharm Biotechnol; 2013; 14(10):913-7. PubMed ID: 24372250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization of broiler chickens against Clostridium perfringens-induced necrotic enteritis.
    Kulkarni RR; Parreira VR; Sharif S; Prescott JF
    Clin Vaccine Immunol; 2007 Sep; 14(9):1070-7. PubMed ID: 17634510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme linked immunosorbent assay for potency testing of vaccines containing Clostridium perfringens type D epsilon-toxoid.
    Pfahler W; Bisesti E; Pereyra JB; Iribarren F
    Zentralbl Veterinarmed B; 1998 Apr; 45(3):133-9. PubMed ID: 9588107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization with recombinant bivalent chimera r-Cpae confers protection against alpha toxin and enterotoxin of Clostridium perfringens type A in murine model.
    Shreya D; Uppalapati SR; Kingston JJ; Sripathy MH; Batra HV
    Mol Immunol; 2015 May; 65(1):51-7. PubMed ID: 25645504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation and immunological characterization of an inactivated canine Clostridium perfringens type A vaccine.
    Xing J; Ji X; Sun Y; Zhu L; Jiang Q; Guo X; Liu J
    Lett Appl Microbiol; 2019 Nov; 69(5):385-390. PubMed ID: 31529707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The use of the toxin binding inhibition test for potency testing of Clostridium novyi type B alpha toxoid vaccines].
    Luick K; Gottschaldt J; Schulze F; Werner E; Erler W; Borrmann E
    Dtsch Tierarztl Wochenschr; 2002 Apr; 109(4):178-82. PubMed ID: 11998370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The titration of clostridial toxoids and antisera in cell culture.
    Knight PA; Burnett C; Whitaker AM; Queminet J
    Dev Biol Stand; 1986; 64():129-36. PubMed ID: 2878845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naturally occurring Clostridium perfringens nontoxic alpha-toxin variant as a potential vaccine candidate against alpha-toxin-associated diseases.
    Schoepe H; Pache C; Neubauer A; Potschka H; Schlapp T; Wieler LH; Baljer G
    Infect Immun; 2001 Nov; 69(11):7194-6. PubMed ID: 11598102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological and immunological studies on toxoids vaccine as a successful alternative in controlling clostridial infection in broilers.
    Saleh N; Fathalla SI; Nabil R; Mosaad AA
    Anaerobe; 2011 Dec; 17(6):426-30. PubMed ID: 21664285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.
    Karczewski J; Zorman J; Wang S; Miezeiewski M; Xie J; Soring K; Petrescu I; Rogers I; Thiriot DS; Cook JC; Chamberlin M; Xoconostle RF; Nahas DD; Joyce JG; Bodmer JL; Heinrichs JH; Secore S
    Vaccine; 2014 May; 32(24):2812-8. PubMed ID: 24662701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.